You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology.

This podcast is intended for health care professionals only.

Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape.

Hi, everyone.

This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for May 30th, 2025.

This week, listener feedback, CRT versus CSP, clues on the ECG, beta blockers after MI, novel approaches to LDL cholesterol lowering, and ICD decisions in cardiac sarcoidosis.

First up is some listener feedback. Dr. Steve Dixon, a heartfire cardiologist from Kansas City writes via email to pushback on my persistent skepticism about rapid titration of Godline-directed medical therapy in

hardfire.

SD says, I am right about the strong hardfire trial which used cardiologists for the majority

of follow-of visits.

And while cards-led care may currently be the case in many clinics across the country, he writes,

times are changing.

Hospitals, PCPs, and advanced practice practitioners are becoming more comfortable with these

life-saving medication classes.

And the future of heart failure care isn't just the burden of cardiologists, but internal medicine where there

are more reinforcements. Dr. Dixon says that in his clinic, they use a four-weeks four-meds program

for patients with Hefref, mainly through nurse practitioners that he guides and manage. He said it's

quite an aggressive program, but I can assure

you that my CEO of the hospital loves seeing his readmissions rates drop. Now my comment to this

is that I fully support programs like four weeks, four meds programs. It's a great idea. But of course,

this takes administrative support.

It takes champions, incentives.

...